版本:
中国

BRIEF-Protalix Biotherapeutics reports Q1 loss per share $0.07 excluding items

May 10 Protalix Biotherapeutics Inc:

* Protalix Biotherapeutics reports 2017 first quarter results and provides corporate update

* Q1 revenue $2.9 million versus $679,000

* Protalix Biotherapeutics Inc qtrly research and development expenses were $4.6 million, compared to $6.0 million for same period in 2016

* Protalix Biotherapeutics - on March 31, 2017 Co had $48.0 million of cash and cash equivalents, which is currently projected to fund operations into 2019

* Q1 loss per share $0.07 excluding items

* Q1 earnings per share view $-0.09, revenue view $2.6 million -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐